# Tvardi Therapeutics, Inc.: overview TVRD · Nasdaq · CIK 1346830 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31 Pages: [Overview](/companies/tvrd.md) · [Financials](/companies/tvrd/financials.md) · [Filings](/companies/tvrd/filings.md) · [Insiders](/companies/tvrd/insiders.md) Latest reported revenue: [$2.6m](/filings/0001558370-25-007575.md) for Q1 FY2025, three months to 2025-03-31, from the 10-Q filed May 13, 2025 (XBRL us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax, accession 0001558370-25-007575). ## Last eight quarters | Line item | Unit | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Revenue | $k | [2,556](/filings/0001558370-24-015713.md) | [1,455 d](/filings/0001558370-25-002705.md) | [2,569](/filings/0001558370-25-007575.md) | not reported | not reported | not reported | not reported | not reported | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | [(222.1%)](/filings/0001104659-25-111289.md) | [(742.4%) d](/filings/0001104659-26-037729.md) | [(169.5%)](/filings/0001104659-26-057528.md) | not reported | not reported | not reported | not reported | not reported | | Net margin | % | [(215.7%)](/filings/0001104659-25-111289.md) | [(873.3%) d](/filings/0001104659-26-037729.md) | [(372.9%)](/filings/0001104659-26-096424.md) | not reported | not reported | not reported | not reported | not reported | | Diluted EPS | $ per share | [(2.14)](/filings/0001104659-25-111289.md) | not reported | [(3.72)](/filings/0001104659-26-057528.md) | [(1.00)](/filings/0001104659-26-096424.md) | [(0.59)](/filings/0001104659-25-111289.md) | not reported | [(0.73)](/filings/0001104659-26-057528.md) | [(0.69)](/filings/0001104659-26-096424.md) | | Free cash flow | $k | [(6,655) d](/filings/0001104659-25-111289.md) | [(4,833) d](/filings/0001104659-26-037729.md) | not reported | not reported | not reported | not reported | not reported | not reported | - Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure. ## Last five fiscal years | Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) | | --- | --- | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | [23.0](/filings/0001558370-24-002609.md) | [41.9](/filings/0001558370-25-002705.md) | [21.0](/filings/0001558370-25-002705.md) | [7.1](/filings/0001558370-25-002705.md) | not reported | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | [(386.8%)](/filings/0001558370-24-002609.md) | [(209.1%)](/filings/0001558370-25-002705.md) | [(579.4%)](/filings/0001558370-25-002705.md) | [(393.8%)](/filings/0001104659-26-037729.md) | not reported | | Net margin | % | [(384.1%)](/filings/0001558370-24-002609.md) | [(204.2%)](/filings/0001558370-25-002705.md) | [(565.2%)](/filings/0001558370-25-002705.md) | [(411.9%)](/filings/0001104659-26-037729.md) | not reported | | Diluted EPS | $ per share | [(1.74)](/filings/0001558370-24-002609.md) | [(19.12)](/filings/0001558370-25-002705.md) | [(26.26)](/filings/0001558370-25-002705.md) | [(11.42)](/filings/0001104659-26-037729.md) | [(3.26)](/filings/0001104659-26-037729.md) | | Free cash flow | $m | [(60.1)](/filings/0001558370-24-002609.md) | [(78.8)](/filings/0001558370-25-002705.md) | [(94.5)](/filings/0001558370-25-002705.md) | [(19.4)](/filings/0001104659-26-037729.md) | not reported | - Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing. ## Insider purchases and sales The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/tvrd/insiders.md) None in coverage. ## Funds that report holding it From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md) | Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before | | --- | --- | ---: | ---: | --- | --- | | [Slate Path Capital LP](/funds/1559706.md) | 2026-06-30 | $1.3m | 704,118 | | Unchanged | | [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $654.3k | 344,382 | | Reduced −326 | | [AMERICAN FINANCIAL GROUP INC](/funds/1042046.md) | 2026-06-30 | $425.0k | 223,659 | | Unchanged | | [UBS Group AG](/funds/1610520.md) | 2026-06-30 | $211.2k | 111,133 | | Added +60,679 | | [SILVERCREST ASSET MANAGEMENT GROUP LLC](/funds/1232395.md) | 2026-06-30 | $192.0k | 101,034 | | Unchanged | | [BlackRock, Inc.](/funds/2012383.md) | 2026-06-30 | $181.4k | 95,478 | | Reduced −292,597 | | [RENAISSANCE TECHNOLOGIES LLC](/funds/1037389.md) | 2026-06-30 | $173.7k | 91,409 | | Reduced −691 | | [GEODE CAPITAL MANAGEMENT, LLC](/funds/1214717.md) | 2026-06-30 | $171.7k | 90,350 | | Reduced −91,989 | | [MORGAN STANLEY](/funds/895421.md) | 2026-06-30 | $147.9k | 77,845 | | Added +4,951 | | [Duncan Williams Asset Management, LLC](/funds/2011771.md) | 2026-06-30 | $120.2k | 63,241 | | Unchanged | ## Recent filings [All 797 filings](/companies/tvrd/filings.md) | Filed | Accepted | Form | What it is | Accession | | --- | --- | --- | --- | --- | | 2026-08-14 | 07:10 ET | [10-Q](/filings/0001104659-26-096424.md) | Quarterly report, period 2026-06-30 | 0001104659-26-096424 | | 2026-08-14 | 07:05 ET | [8-K](/filings/0001104659-26-096417.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001104659-26-096417 | | 2026-07-30 | 07:30 ET | [8-K](/filings/0001104659-26-088461.md) | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001104659-26-088461 | | 2026-07-17 | 16:07 ET | [8-K](/filings/0001104659-26-084627.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0001104659-26-084627 | | 2026-07-07 | 07:02 ET | [8-K](/filings/0001104659-26-080930.md) | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001104659-26-080930 | | 2026-06-11 | 16:05 ET | [8-K](/filings/0001104659-26-072930.md) | 5.07 Shareholder vote results | 0001104659-26-072930 | | 2026-05-08 | 07:10 ET | [10-Q](/filings/0001104659-26-057528.md) | Quarterly report, period 2026-03-31 | 0001104659-26-057528 | | 2026-05-08 | 07:05 ET | [8-K](/filings/0001104659-26-057524.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001104659-26-057524 | | 2026-04-23 | 16:10 ET | [DEF 14A](/filings/0001104659-26-047695.md) | Proxy statement, period 2026-06-09 | 0001104659-26-047695 | | 2026-03-31 | 16:10 ET | [10-K](/filings/0001104659-26-037729.md) | Annual report, period 2025-12-31 | 0001104659-26-037729 | ## Latest annual report [Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001104659-26-037729.md), filed Mar 31, 2026. ## Forecast league Not in this season’s league. [This season’s league](/leagues.md) ## About the filer - CIK: 1346830 - Tickers: TVRD - Exchange: Nasdaq - SIC code: 2834 Pharmaceutical Preparations - State of incorporation: DE - Filer category: Non-accelerated filer
Smaller reporting company Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:37 ET. No prices; not investment advice.